In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mylan gets rights to Pfizer's dry powder inhaler platform

Executive Summary

Pfizer Inc. has licensed generics giant Mylan Inc. exclusive rights to develop, manufacture, and commercialize its generic equivalents of GlaxoSmithKline PLC's Advair/Seretide Diskus products, which deliver fixed-dose combinations of fluticasone propionate and salmeterol via a dry powder inhaler to treat asthma and chronic obstructive pulmonary disorder (COPD).
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies